GSK, Jemperli and european union
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...
The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...
And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...
GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
The hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, will be included in the next round of ...
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone ...
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
Shares of GSK PLC GSK inched down 0.51% to £13.57 Friday, on what proved to be an all-around poor trading session for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback